CLDX Q3 2017 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+76.8% YoY

Gross Profit

-$18M-458.5% margin

Operating Income

-$32M-814.5% margin

Net Income

-$26M-671.8% margin

EPS (Diluted)

$-3.05

QoQ Revenue Growth

+2.5%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$25M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$319M

Total Liabilities

$100M

Stockholders' Equity

$219M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+76.8%
Gross Profit	-$18M	-$47M	+61.4%
Operating Income	-$32M	-$30M	-6.6%
Net Income	-$26M	-$30M	+10.9%